Abstract colorectal cancer (crc) is the third most common type of cancer and the second leading cause of cancer deaths worldwide Surgery or surgery plus radiotherapy and/or chemotherapy for patients with metastatic crc (mcrc) were accepted as the main therapeutic strategies until the early 2000s, when targeted drugs, like cetuximab and bevacizumab, were developed The use of targeted drugs in. The approval was based on results from codebreak 300, a phase 3. Msk investigators have led much of the research that resulted in this combined drug approval. On november 8, 2023, the food and drug administration approved fruquintinib (fruzaqla, takeda pharmaceuticals, inc.) for adult patients with metastatic colorectal cancer (mcrc) who received prior.
OPEN
